Real-world barriers and safety of initiating sodium-glucose co-transporter 2 inhibitor treatment immediately following an acute cardiac event in people with diabetes

Sarah A Hitchen; Nick S R Lan; James M Rankin; Robert Larbalestier; Bu B Yeap; P Gerry Fegan

doi:10.1016/j.jdiacomp.2021.108057

Real-world barriers and safety of initiating sodium-glucose co-transporter 2 inhibitor treatment immediately following an acute cardiac event in people with diabetes

Sarah A Hitchen, Nick S R Lan, James M Rankin, Robert Larbalestier, Bu B Yeap, P Gerry Fegan

Internal Medicine

Research output: Contribution to journal › Article › peer-review

2 Citations (Scopus)

Abstract

In this real-world study, the main barriers for not initiating SGLT2 inhibitor therapy early after an acute cardiac event are prescribing criteria around glycated haemoglobin and renal function. Initiation of SGLT2 inhibitors near to, or at, hospital discharge following the cardiac event was not associated with 30-day diabetic ketoacidosis readmissions.

Original language	English
Article number	108057
Journal	Journal of Diabetes and Its Complications
Volume	35
Issue number	12
Early online date	29 Sept 2021
DOIs	https://doi.org/10.1016/j.jdiacomp.2021.108057
Publication status	Published - Dec 2021

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.jdiacomp.2021.108057

Cite this

Hitchen, S. A., Lan, N. S. R., Rankin, J. M., Larbalestier, R., Yeap, B. B., & Fegan, P. G. (2021). Real-world barriers and safety of initiating sodium-glucose co-transporter 2 inhibitor treatment immediately following an acute cardiac event in people with diabetes. Journal of Diabetes and Its Complications, 35(12), Article 108057. https://doi.org/10.1016/j.jdiacomp.2021.108057

@article{b29072eeb89144a1ad0a9fb2d5b53829,

title = "Real-world barriers and safety of initiating sodium-glucose co-transporter 2 inhibitor treatment immediately following an acute cardiac event in people with diabetes",

abstract = "In this real-world study, the main barriers for not initiating SGLT2 inhibitor therapy early after an acute cardiac event are prescribing criteria around glycated haemoglobin and renal function. Initiation of SGLT2 inhibitors near to, or at, hospital discharge following the cardiac event was not associated with 30-day diabetic ketoacidosis readmissions.",

author = "Hitchen, {Sarah A} and Lan, {Nick S R} and Rankin, {James M} and Robert Larbalestier and Yeap, {Bu B} and Fegan, {P Gerry}",

year = "2021",

month = dec,

doi = "10.1016/j.jdiacomp.2021.108057",

language = "English",

volume = "35",

journal = "Journal of Diabetes and Its Complications",

issn = "1056-8727",

publisher = "Elsevier",

number = "12",

}

Real-world barriers and safety of initiating sodium-glucose co-transporter 2 inhibitor treatment immediately following an acute cardiac event in people with diabetes. / Hitchen, Sarah A; Lan, Nick S R; Rankin, James M et al.
In: Journal of Diabetes and Its Complications, Vol. 35, No. 12, 108057, 12.2021.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Real-world barriers and safety of initiating sodium-glucose co-transporter 2 inhibitor treatment immediately following an acute cardiac event in people with diabetes

AU - Hitchen, Sarah A

AU - Lan, Nick S R

AU - Rankin, James M

AU - Larbalestier, Robert

AU - Yeap, Bu B

AU - Fegan, P Gerry

PY - 2021/12

Y1 - 2021/12

N2 - In this real-world study, the main barriers for not initiating SGLT2 inhibitor therapy early after an acute cardiac event are prescribing criteria around glycated haemoglobin and renal function. Initiation of SGLT2 inhibitors near to, or at, hospital discharge following the cardiac event was not associated with 30-day diabetic ketoacidosis readmissions.

AB - In this real-world study, the main barriers for not initiating SGLT2 inhibitor therapy early after an acute cardiac event are prescribing criteria around glycated haemoglobin and renal function. Initiation of SGLT2 inhibitors near to, or at, hospital discharge following the cardiac event was not associated with 30-day diabetic ketoacidosis readmissions.

U2 - 10.1016/j.jdiacomp.2021.108057

DO - 10.1016/j.jdiacomp.2021.108057

M3 - Article

C2 - 34610888

SN - 1056-8727

VL - 35

JO - Journal of Diabetes and Its Complications

JF - Journal of Diabetes and Its Complications

IS - 12

M1 - 108057

ER -

Real-world barriers and safety of initiating sodium-glucose co-transporter 2 inhibitor treatment immediately following an acute cardiac event in people with diabetes

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this